Translational Research (TR) Company, a division of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), has developed proprietary technology for nasal drug delivery, μco™ System (
“myu-co” system). The system is comprised of two technological elements, powder carrier technology and delivery device technology. In addition to licensing out platform technology and
products developed in-house to pharmaceutical companies, SNBL provides support for R&D of drug products applying the group’ s vast experience and capacity for drug development as
a contract research organization (CRO) and its state-of-the-art preclinical and clinical study facilities recognized world-wide.
This website uses cookies.
This website uses cookies to give you the best online experience. Please let us know if you agree by clicking on the “Accept” option below. If you’d like to find out more about the cookies we use and set your individual cookie preferences, please review our Cookie Policy. More details here: Cookie Policy